

Biomagnetics Diagnostics Corp.

(A Nevada Corporation)

INFORMATION AND DISCLOSURE STATEMENT

***Quarterly Report
September 30, 2012***

OTCPK: BMGP

Item 1 Exact name of the issuer and the address of its principal executive offices.

A) The exact name of the Issuer and its predecessor (if any).

Biomagnetics Diagnostics Corp. has been the name of the issuer since December 7, 2006. Previously, the issuer was named as follows:

<u>Date of Name Change</u>	<u>Name</u>
February 26, 1997	JRL ENTERPRISES, INC.
August 28, 2000	FUTURNET INTERNET SERVICES, INC.
October 26, 2000	FUTURENET INTERNET SERVICES, INC.
April 26, 2001	SEPTEMBER PROJECT, INC.
April 27, 2001	SEPTEMBER GROUP, INC.
February 25, 2002	DESIGN MARKETING CONCEPTS, INC
October 29, 2002	PROSPORTSBOOK.NET, INC.
February 27, 2003	IBISES INTERNATIONAL, INC.
March 3, 2006	BIOMAG CORP.
December 7, 2006	BIOMAGNETICS DIAGNOSTICS CORP.

B) The address of the issuer's principal executive offices.

Address: 8864 Greenback Ln. Ste E
Orangevale, CA. 95662
Phone: (916) 987-7078
Fax: (916) 987-7988

Biomagnetics Diagnostics Corp.

(A Nevada Corporation)

Item 2 Shares outstanding

The number of shares or total amount of the securities outstanding for each class of securities authorized.

<i>Common Stock</i>	<i>Most Recent Fiscal Quarter</i>	<i>Fiscal Year</i>	<i>Fiscal Year</i>
<i>(i) Period end date;</i>	<i>09/30/12</i>	<i>12/31/11</i>	<i>12/31/10</i>
<i>(ii) Number of shares authorized;</i>	<i>200,000,000</i>	<i>200,000,000</i>	<i>100,000,000</i>
<i>(iii) Number of shares outstanding;</i>	<i>177,161,072</i>	<i>115,455,517</i>	<i>76,261,499</i>
<i>(iv) Freely tradable shares (public float);</i>	<i>93,242,141</i>	<i>47,557,078</i>	<i>34,944,000</i>
<i>(v) Total number of beneficial shareholders; and</i>	<i>1522</i>	<i>1538</i>	<i>1428</i>
<i>(vi) Total number of shareholders of record</i>	<i>351</i>	<i>348</i>	<i>528</i>

<i>Preferred Stock</i>	<i>Most Recent Fiscal Quarter</i>	<i>Fiscal Year</i>	<i>Fiscal Year</i>
<i>(i) Period end date;</i>	<i>09/30/12</i>	<i>12/31/11</i>	<i>12/31/10</i>
<i>(ii) Number of shares authorized;</i>	<i>10,000,000</i>	<i>10,000,000</i>	<i>10,000,000</i>
<i>(iii) Number of shares outstanding;</i>	<i>1,000,000</i>	<i>1,000,000</i>	<i>1,000,000</i>
<i>(iv) Freely tradable shares (public float);</i>	<i>0</i>	<i>0</i>	<i>0</i>
<i>(v) Total number of beneficial shareholders; and</i>	<i>1</i>	<i>1</i>	<i>1</i>
<i>(vi) Total number of shareholders of record</i>	<i>1</i>	<i>1</i>	<i>1</i>

Item 3 Interim Financial Statements

The following financials are included and attached hereto and incorporated herein by reference:

- Balance Sheet
- Statements of Operation
- Statement of Stockholders' Equity (Deficit)
- Statement of Cash Flow
- Notes to Unaudited Financial Statements

The financial statements can be found at <http://www.otcmarkets.com/stock/BMGP/financials>

Biomagnetics Diagnostics Corp.

(A Nevada Corporation)

Item 4 Management's discussion and analysis or plan of operation

A) Plan of Operation

1. Describe the issuer's plan of operation for the next twelve months:

- i. A discussion of how long the issuer can satisfy its cash requirements and whether it will have to raise additional funds in the next twelve months; we expect it will be necessary to raise \$2,000,000 in the next twelve months, which will satisfy our future cash requirements

The issuer may experience problems; delays, expenses and difficulties sometimes encountered by an enterprise in the registrant's stage, many of which are beyond the issuer's control. These include, but are not limited to, unanticipated problems relating to additional costs and expenses that may exceed current estimates and competition.

- ii. a summary of any product research and development that the issuer will perform for the term of the plan;

The issuer is developing patented medical diagnostics equipment and immunoassays. We are currently working with Las Alamos National Laboratory to develop a Tuberculosis and Cholera assay in conjunction with a diagnostics unit that can read the results of these assays in a clinical setting.

- iii. any expected purchase or sale of plant and significant equipment;

None

- iv. any expected significant changes in the number of employees;

None

B) Management's Discussion and Analysis of Financial Condition and Results of Operations.

Trends and Uncertainties. Demand for the issuer's products will be dependent on, among other things, general economic conditions which are cyclical in nature. Inasmuch as a major portion of the issuer's activities are the receipt of revenues from its products, the issuer's business operations may be adversely affected by the registrant's competitors and prolonged recessionary periods.

There are no other known trends, events or uncertainties that have or are reasonably likely to have a material impact on the issuer's short term or long term liquidity. Sources of liquidity both internal and external will come from the sale of the issuer's products as well as the private sale of the issuer's stock. There are no material commitments for capital expenditure at this time. There are no trends, events or uncertainties that have had or are reasonably expected to have a material

Biomagnetics Diagnostics Corp.

(A Nevada Corporation)

impact on the net sales or revenues or income from continuing operations. There are no significant elements of income or loss that does not arise from the issuer's continuing operations.

There are no other known causes for any material changes from period to period in one or more line items of the issuer's financial statements.

Capital and Source of Liquidity. The issuer currently has no material commitments for capital expenditures but will spend capital on engineering when funds become available.

The issuer believes that there will not be sufficient capital from revenues to conduct operations for the next twelve months. We expect it will be necessary to raise \$2,000,000 in the next twelve months, which will satisfy our future cash requirements.

The sole director has no immediate offering plans in place. The sole director shall determine the amount and type of financing as the issuer's financial situation dictates.

For the nine months ended September 30, 2012, the issuer received proceeds from note-related parties of \$9,266 and received net proceeds from notes payable of \$63,901. As a result, for the nine months ended September 30, 2012, the issuer had net cash provided by financing activities of \$160,867.

Comparatively, for the nine months ended September 30, 2011, the issuer received proceeds from note-related parties of \$8,618, and received proceeds from the sale of common stock of \$290,318. As a result, for the nine months ended September 30, 2011, the issuer had net cash provided by financing activities of \$301,320.

For the year ended December 31, 2011, the issuer did not purchase equipment and had patent expenses of \$1,524 resulting in net cash used by investing activities of \$1,524.

For the year ended December 31, 2011, the issuer purchased equipment of \$1,329 resulting in net cash used by investing activities of \$1,329.

For the year ended December 31, 2011, the issuer made payments on Notes Payable-Related Parties of \$64, made payments on Notes Payable of \$29,282 and received proceeds from the sale of its common stock of \$300,318. As a result, the issuer had cash provided by financing activities of \$270,972 for the year ended December 31, 2011.

Biomagnetics Diagnostics Corp.

(A Nevada Corporation)

For the year ended December 31, 2010, the issuer repaid Notes Payable of \$265,233, received proceeds from Notes Payable-Related Parties of \$9,538 and received proceeds from the sale of its common stock of \$566,900. As a result, the issuer had cash provided by financing activities of \$301,205 for the year ended December 31, 2010.

On a long term basis, liquidity is dependent on commencement of full operation and receipt of revenues.

Results of Operations. Operating expenses for the three months ended September 30, 2012 were \$72,553. These expenses consisted of general and administrative expenses of \$40,957, payroll of \$29,066, and professional consulting of \$2,530

Operating expenses for the three months ended September 30, 2011 were \$149,022. These expenses consisted of general and administrative expenses of \$48,071, payroll of \$45,213, professional and consulting of \$107,937, and research and development of \$(52,199). The decrease in net loss from operations was due to a decrease in professional and consulting obligations.

For the nine months ended September 30, 2012, the issuer did not receive any revenues. Net loss for the nine months ended June 30, 2012 was \$(304,725). These expenses consists \$145,971 general and administration, \$84,485 in payroll, \$73,769 in professional and consulting, and \$500 for marketing.

For the nine months ended September 30, 2011, the issuer did not receive any revenues. Net loss for the nine months ended September 30, 2011 was \$(706,146). These expenses consisted of general and administrative at \$154,400, Payroll of 141,463, Professional and consulting services were \$283,893 and research and development was 126,390.

For the year ended December 31, 2011, the issuer did not receive any revenues. Operating expenses for the year ended December 31, 2011 were \$850,107. These expenses consisted of general and administrative expenses of \$167,381, payroll of \$167,299, professional and consulting fees of \$389,037

For the year ended December 31, 2010, the issuer did not receive any revenues. Operating expenses for the year ended December 31, 2010 were 1,066,363. These expenses consisted of general and administrative expenses of \$96,153, payroll of \$139,363, professional and consulting fees of \$640,775, marketing of \$13,404 and research and development costs of \$144,668. The increase in payroll was due to increased administrative operations

Item 5 Legal Proceedings

As of June 30, 2012, the issuer has meet its financial responsibility and has a zero balance which includes attorney fees associated with a settlement of a collection action taken by a note holder. A summary of the provisions of the original settlement, default and current agreement follows:

Biomagnetics Diagnostics Corp.

(A Nevada Corporation)

On November 20, 1998, the issuer's predecessor executed a note for \$100,000 at \$10% interest with a married couple who were very supportive of the issuer's vision and who extended the due date of the note on several occasions. On November 25, 2003, a marital trust created on behalf of the couple took possession of the note with the daughter as the Trustee. After the death of the couple, the Trustee entered a complaint for breach of promissory note with the Sacramento County Superior Court on October 25, 2006. The court set trial action for March 10, 2008 on which date the parties reached a settlement.

The issuer agreed to a stipulation of judgment in the amount of \$160,000 to be filed if the issuer defaulted on an agreement to pay \$120,000 plus 10% interest per annum with a \$25,000 payment on March 11, 2008 and \$10,000 monthly installments beginning April 10, 2008 until paid off. In the event of default, the issuer would get credit for any payments made and become responsible for costs and attorney fees from March 11, 2008. The note holder agreed to dismiss the remainder action with prejudice and each party to bear its own fees and costs if payments were timely made.

The issuer defaulted after making the initial \$25,000 payment and one \$10,000 monthly payment. The holder executed the stipulation of judgment and proceeded with collection action.

On October 3, 2009, the holder's attorney represented that the holder agreed to forbear further action against the assets of the issuer upon the receipt of \$50,000 by October 9, 2009 and receipt of monthly payments of \$4,000 until principal, interest and costs including reasonable attorney fees are paid in full. The issuer has made full restitution and is free and clear of any further legal or monetary responsibilities.

Item 6 Defaults upon senior securities

There are no material defaults in the payment of principal, interest, a sinking or purchase fund installment, or any other material default not cured within 30 days, with respect to any indebtedness of the issuer exceeding 5% of the total assets of the issuer.

Item 7 Other information.

None

Item 8 Exhibits

None

Biomagnetics Diagnostics Corp.

(A Nevada Corporation)

Item 9 Certifications

I, Clayton M. Hardman, certify that:

1. I have reviewed this quarterly disclosure statement of Biomagnetics Diagnostics Corp.
2. Based on my knowledge, this disclosure statement does not contain any untrue statements of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered this disclosure statement; and
3. Based on my knowledge, the financial statements, and other financial information included or incorporated by reference in this disclosure statement, fairly present in all material respects the financial condition, results of operations and cash flows of the issuer as of, and for the periods presented in this disclosure statement

Dated this 4th of September 2012

Biomagnetics Diagnostics Corp.

By: /s/Clayton M. Hardman

Name: Clayton M. Hardman
Position: President, CEO and Acting CFO
Phone: (916) 987-7078
Email: chardman@biomagneticsbmgp.com
Web-page: www.biomagneticsbmgp.com